# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

# **Multiple Technology Appraisal (MTA)**

# Prasugrel with percutaneous coronary intervention for treating acute coronary syndrome (review of TA182)

# Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Lilly UK (prasugrel)	Allied Health Professionals Federation
Dationt/source average	Board of Community Health Councils in
Patient/carer groups  Action Heart	Wales
	British National Formulary     Core Ouglity Commission
Afiya Trust     Plack Health Agency	Care Quality Commission
<ul><li>Black Health Agency</li><li>Blood Pressure UK</li></ul>	Commissioning Support Appraisals     Service
British Cardiac Patients Association	Department of Health, Social Services
Cardiac Risk in the Young	and Public Safety for Northern Ireland
Coronary Prevention Group	Healthcare Improvement Scotland
Equalities National Council	Medicines and Healthcare products
Heart Care Partnership	Regulatory Agency
HEART UK	<ul> <li>National Association for Primary Care</li> </ul>
Independent Age	National Pharmacy Association
Muslim Council of Britain	NHS Alliance
Muslim Health Network	<ul> <li>NHS Commercial Medicines Unit</li> </ul>
<ul> <li>Network of Sikh Organisations</li> </ul>	NHS Confederation
<ul> <li>South Asian Health Foundation</li> </ul>	<ul> <li>Public Health Wales NHS Trust</li> </ul>
Specialised Healthcare Alliance	Scottish Medicines Consortium
Somerville Foundation	
	Comparator manufacturers
Professional groups	Actavis UK (aspirin, clopidogrel)
British Association for Nursing in	Arrow Generics (aspirin, clopidogrel)  Agrico Blanco (alsociate and l)
Cardiovascular Care	Aspire Pharma (clopidogrel)     AstroZanosa (tipagralar)
British Association for Services to the  Eldorly	AstraZeneca (ticagrelor)     Rayor (aspirin)
<ul><li>Elderly</li><li>British Atherosclerosis Society</li></ul>	<ul><li>Bayer (aspirin)</li><li>Beacon Pharmaceuticals (clopidogrel)</li></ul>
British Cardiovascular Intervention	Bristol Laboratories (aspirin)
Society	Bristol-Myers Squibb (clopidogrel)
British Cardiovascular Society	Dexcel Pharma (aspirin, clopidogrel)
British Geriatrics Society	Dr Reddy's Laboratories UK
British Heart Foundation	(clopidogrel)
British Nuclear Cardiology Society	<ul> <li>Intrapharm Laboratories (aspirin)</li> </ul>
British Society for Heart Failure	Martindale Pharmaceuticals (aspirin)

National Institute for Health and Clinical Excellence

Provisional matrix for the single technology appraisal of prasugrel with percutaneous coronary intervention for treating acute coronary syndrome (review of TA182)

Issue date: March 2013 Page 1 of 4

#### Consultees Commentators (no right to submit or appeal) British Society of Cardiovascular Mylan (clopidogrel) **Imaging** Reckitt Benckiser (aspirin) College of Emergency Medicine Sandoz (aspirin, clopidogrel) National Heart Forum Sanofi (clopidogrel) Primary Care Cardiovascular Society Teva UK (aspirin, clopidogrel) Royal College of General Thornton & Ross (aspirin) **Practitioners** Wockhardt UK (aspirin, clopidogrel) Royal College of Nursing Royal College of Pathologists Relevant research groups Royal College of Physicians • Antithrombotic Trialists' (ATT) Royal Pharmaceutical Society Collaboration British Society for Cardiovascular Royal Society of Medicine Research United Kingdom Clinical Pharmacy Cardiac and cardiology research dept, Association **Barts** Vascular Society Central Cardiac Audit Database Cochrane Heart Group Others Department of Health Cochrane Hypertension Group • Cochrane Peripheral Vascular Derbyshire PCT Cluster **Diseases Group** Lancashire PCT Cluster Welsh Government Cochrane Stroke Group CORDA European Council for Cardiovascular Research Health Research Authority MRC Clinical Trials Unit National Heart Research Fund National Institute for Health Research Research Institute for the Care of Older People Wellcome Trust Assessment Group Liverpool Reviews and Implementation Group National Institute for Health Research Health Technology Assessment Programme Associated Guideline Groups National Clinical Guidelines Centre Associated Public Health Groups None

Intervention for treating acute coronary syndrome (review of TA1 Issue date: March 2013

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

# **MTA Definitions:**

# **Consultees**

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional

National Institute for Health and Clinical Excellence Provisional matrix for the single technology appraisal of prasugrel with percutaneous coronary intervention for treating acute coronary syndrome (review of TA182) Issue date: March 2013 organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

# **Commentators**

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

# Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.